Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission

Worldwide, the scientific community is working on the development of a vaccine against HIV. Meanwhile, research is also focused on the reduction of the spread of the virus by the application of a microbicide gel to protect users during intercourse which is a time of first exposure to virus. To date, few treatments that block virus entry have shown promising protection.

Dereuddre-Bosquet et al. engineered peptides named "miniCD4s" because they mimic the CD4 receptor used by HIV to gain entry into immune cells of the body. The study shows that the miniCD4s blocks HIV entry into isolated cells in a dish and tissue models that mimic mucous membranes which are points of virus entry. The authors then formulated miniCD4s at 0.3% in a microbicide gel that was vaginally applied to six female cynomolgus macaques monkeys for one hour before the animals were given a high dose of the virus also in the vagina. This dose would ordinarily make the animals highly infection but instead, five of the six were completely protected from HIV infection. No trace of virus was found in any body tissue. They were also unable to detect any antibodies to the virus in the plasma of the animals, indicating that the virus was completely repelled and there was full protection.

This study provides a proof of principle that for a a promising strategy for the prevention and protection against HIV ransmission during sexual intercourse. Importantly, the protection was demonstrated in a non human primate model which represents an essential step prior needed to progress to a prospective clinical trial.

More information: PLOS Pathogens dx.plos.org/10.137… ppat.1003071

Journal reference: PLoS Pathogens

Provided by Public Library of Science